What is JSPR stock price today?

JSPR (Jasper Therapeutics Inc) stock is trading at $1.05 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is JSPR stock going up or down today?

JSPR stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy JSPR stock now?

The decision to buy JSPR depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is JSPR a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for JSPR based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is JSPR stock overvalued or undervalued?

Use our DCF valuation calculator to determine if JSPR is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is JSPR's P/E ratio?

P/E ratio data for JSPR will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is JSPR's market cap?

JSPR (Jasper Therapeutics Inc) has a market capitalization of $0.03 billion, making it a small-cap stock.

What is JSPR's price to book ratio?

JSPR trades at a price-to-book (P/B) ratio of 6.29, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does JSPR pay dividends?

JSPR does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is JSPR's dividend yield?

JSPR does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is JSPR stock a good long-term investment?

JSPR's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is JSPR's revenue growth rate?

Revenue growth data for JSPR is available on our dashboard with detailed financial statement analysis.

Profitability metrics for JSPR are available on our dashboard with complete income statement analysis.

What are the risks of investing in JSPR?

Key risks for JSPR include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does JSPR compare to its competitors?

Compare JSPR to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize JSPR's performance and positioning.

What is JSPR's stock price target for 2026?

Our AI model provides price targets for JSPR based on fundamental analysis: Bull case $1.37 (+30%), Base case $1.21 (+15%), Bear case $0.95 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about JSPR?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for JSPR. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is JSPR's next earnings report?

JSPR reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

JSPR - Jasper Therapeutics Inc

NYSE * Health Care * Biotechnology

$1.05

+$0.12 (+12.61%)

About Jasper Therapeutics Inc

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

JSPR Key Statistics

Market Cap

$26.10M

P/B Ratio

6.29

EPS

$-4.09

Employees

How JSPR Compares to Peers

JSPR is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
JSPR(This stock)	$26.10M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Jasper Therapeutics Inc Company Information

Headquarters: California; U.S.A
Website: jaspertx.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 16, 2026 at 12:34 AM EDT

Ready to invest in JSPR?

Commission-free trading available. Affiliate links.

Upcoming Events for JSPR

Dashboard

Enter a ticker to analyze